Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Prioritization of delayed vaccination for pandemic influenza

1. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261

Limited production capacity and delays in vaccine development are major obstacles to vaccination programs that are designed to mitigate a pandemic influenza. In order to evaluate and compare the impact of various vaccination strategies during a pandemic influenza, we developed an age/risk-structured model of influenza transmission, and parameterized it with epidemiological data from the 2009 H1N1 influenza A pandemic. Our model predicts that the impact of vaccination would be considerably diminished by delays in vaccination and staggered vaccine supply. Nonetheless, prioritizing limited H1N1 vaccine to individuals with a high risk of complications, followed by school-age children, and then preschool-age children, would minimize an overall attack rate as well as hospitalizations and deaths. This vaccination scheme would maximize the benefits of vaccination by protecting the high-risk people directly, and generating indirect protection by vaccinating children who are most likely to transmit the disease.
  Article Metrics

Keywords optimal; pandemic; delay; Influenza; vaccination; H1N1.

Citation: Eunha Shim. Prioritization of delayed vaccination for pandemic influenza. Mathematical Biosciences and Engineering, 2011, 8(1): 95-112. doi: 10.3934/mbe.2011.8.95


This article has been cited by

  • 1. Matt J. Keeling, Andrew Shattock, Optimal but unequitable prophylactic distribution of vaccine, Epidemics, 2012, 4, 2, 78, 10.1016/j.epidem.2012.03.001
  • 2. Louise E. Lansbury, Sherie Smith, Walter Beyer, Emina Karamehic, Eva Pasic-Juhas, Hana Sikira, Ana Mateus, Hitoshi Oshitani, Hongxin Zhao, Charles R. Beck, Jonathan S. Nguyen-Van-Tam, Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis, Vaccine, 2017, 35, 16, 1996, 10.1016/j.vaccine.2017.02.059

Reader Comments

your name: *   your email: *  

Copyright Info: 2011, , licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved